Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Short and Long-Term Toxicities of Allogeneic Stem Cell Transplant for Adult Patients with Sickle Cell Disease

Blood (2024) 144 (Supplement 1): 2173.

https://doi.org/10.1182/blood-2024-194049

Published: 2024

Journal Articles

Outpatient Hematopoietic Stem Cell Transplant for Adult Sickle Cell Disease Patients Is Safe, Reduce Inpatient Bed Utilization and Improve Access to Care

Blood (2024) 144 (Supplement 1): 518.

https://doi.org/10.1182/blood-2024-198792

Published: 2024

Journal Articles

An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease

Blood (2024) 143 (25): 2654–2665.

https://doi.org/10.1182/blood.2023023301

Published: 2024

Includes: Supplemental data

Journal Articles

Favorable Fertility Outcome in a Large Cohort of Sickle Cell Disease Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Blood (2023) 142 (Supplement 1): 240.

https://doi.org/10.1182/blood-2023-178128

Published: 2023

Journal Articles

Excellent Outcomes of HLA Matched Related Donor Transplant for Adults with Severe Sickle Cell Disease Using a Non-Myeloablative Conditioning with Thiotepa and Post-Transplant Cyclophosphamide: Multi-Center International Experience

Reem Alasbali, Mohsen Alzahrani, Saud Alhayli, Walid Rasheed, Phavina Akhom, Karina Wilkerson, Mohammed Essa, Riad Elfakih, Bader Alahmari, Hadeel Samarkandi, Syed Osman Ahmed, Ayman Saad, Hazza A. Alzahrani, Fahad Almohareb, Mahmoud Aljurf, Adetola A. Kassim, Ali D Alahmari

Blood (2023) 142 (Supplement 1): 1042.

https://doi.org/10.1182/blood-2023-189914

Published: 2023

Journal Articles

Comparison of Interobserver Agreement between the 4T and the HIT Expert Probability (HEP) Scores: We Agreed Not to Agree

Abdulrahman Al Raizah, Rawan Almohamdy, Khalid Alharbi, Albarra Madkhali, Rahaf ElHussein Salem, Mohammed Alshuaibi, Abdullah S. Al Saleh, Mohsen Alzahrani, Ayman Hejazi, Hind Salama, Ahmed Alaskar

Blood (2023) 142 (Supplement 1): 5430.

https://doi.org/10.1182/blood-2023-181649

Published: 2023

Journal Articles

Clinical Features and Outcomes of Hemophagocytic Lymphohistiocytosis Secondary to Lymphoma: Insights from a Tertiary Center in Saudi Arabia

Rahaf ElHussein Salem, Mohamed H. Omer, Hind Salama, Ayman Alhejazi, Ayman Ibrahim, Sara Qubaiban, Abdulaziz Abdullah Alahmary, Maryam AlMutairi, Abdulrahman Al Raizah, Mohsen Alzahrani, Ahmed Alaskar

Blood (2023) 142 (Supplement 1): 6278.

https://doi.org/10.1182/blood-2023-188397

Published: 2023

Journal Articles

Impact of Genetic Variations on Thrombotic Risk in Saudis with Sickle Cell Disease

Farjah Algahtani, Mohammad Alshabeeb, Mohsen Alzahrani, Deemah Alwadaani, Hala Alajmi, Salah Abohelaika, Hussain Alsaeed, Mamoon Rashid, Barrak Alsomaie, Abdullah Alzayed, Ann Daly

Blood (2023) 142 (Supplement 1): 5553.

https://doi.org/10.1182/blood-2023-190003

Published: 2023

Journal Articles

Sickle Cell Disease (SCD) Burden on Patients Treated With Hydroxyurea (HU): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)

Hatoon M. Ezzat, Abdullah Hasan Al Zayed, Hussain H. Al Saeed, Mohamed Al Darwish, Muneer Albagshi, Hafiz Malhan, Ahmad Tarawah, Aljawhara Al Manea, Iman Alhazmi, Mohamed Qari, Azzah Alzahrani, Mohsen Alzahrani, Wesam Soliman, Farid Askar, Al Shaimaa Yassin, Wasil Jastaniah

Blood (2022) 140 (Supplement 1): 10879–10880.

https://doi.org/10.1182/blood-2022-166723

Published: 2022

Journal Articles

Effect of ABO Mismatch and RBC Alloimmunization on the Outcomes of Patients with Sickle Cell Disease Undergoing Hematopoietic Stem Cell Transplantation

Blood (2022) 140 (Supplement 1): 7599–7600.

https://doi.org/10.1182/blood-2022-158787

Published: 2022

Journal Articles

Early Donor T-Cell Engraftment Is Critical for Immune Tolerance in Reduced Intensity Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide for Sickle Cell Disease: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC 2 )

Blood (2022) 140 (Supplement 1): 10462–10464.

https://doi.org/10.1182/blood-2022-170552

Published: 2022

Journal Articles

Outcome of Advanced Stage Diffuse Large B-Cell Lymphoma; Experience from Saudi Arabia

Ahmed Alaskar, Naila Shaheen, Farhan Khalid, Mohsen Alzahrani, Giamal Edin Gmati, Bader Alahmari, Hind Salama, Bayan Albadah, May Anne Mendoza, Maryam Almotairi, Rania Jaha, Ayman Alhejazi

Blood (2022) 140 (Supplement 1): 11974–11976.

https://doi.org/10.1182/blood-2022-165054

Published: 2022

Journal Articles

Real Life Analysis of Brentuximab Vedotin (BV) Use As Consolidation Therapy in Patients with Hodgkin's Lymphoma (HL) with High Risk of Relapse after Autologous Stem Cell Transplantation (ASCT). a Retrospective Analysis of the EBMT Lymphoma Working Party

Blood (2022) 140 (Supplement 1): 6558–6560.

https://doi.org/10.1182/blood-2022-167644

Published: 2022

Journal Articles

Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC 2 )

Blood (2022) 140 (Supplement 1): 2383–2385.

https://doi.org/10.1182/blood-2022-165229

Published: 2022

Journal Articles

Evidence Gaps in the Management of Patients with Sickle Cell Disease (SCD) by Non-specialist Healthcare Professionals (HCPs): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)

Wasil Jastaniah, Abdullah Hasan Al Zayed, Hussain H. Al Saeed, Mohamed Al Darwish, Muneer Albagshi, Hafiz Malhan, Ahmad Tarawah, Aljawhara Al Manea, Iman Alhazmi, Mohamed Qari, Azzah Alzahrani, Mohsen Alzahrani, Wesam Soliman, Farid Askar, Sukina Almustafa, Hatoon M. Ezzat

Blood (2022) 140 (Supplement 1): 5133–5134.

https://doi.org/10.1182/blood-2022-166880

Published: 2022

Journal Articles

Discontinuation of Tyrosine Kinase Inhibitor Therapy and Treatment-Free Remission in Chronic-Phase Chronic Myeloid Leukemia: An Observational Retrospective Multi-Center Study

Aamer Aleem, Farjah Alqahtani, Ahmed Jamal, Nora A. Alkhudair, Mashail Alghafis, Hajar Wan Zuki Siti, Bader Alahmari, Hend Salama, Giamal Edin Gmati, Mohsen Alzahrani, Ayman Alhejazi, Naila A. Shaheen, Abdullah M Alrajhi, Mansour Alfayez, Zafar Iqbal, Ahmed Alaskar

Blood (2022) 140 (Supplement 1): 12220–12221.

https://doi.org/10.1182/blood-2022-168926

Published: 2022

Journal Articles

Higher Efficacy of TBI + Cyclophosphamide Than TBI + Fludarabine As Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia: An Analysis By the Acute Leukemia Working Party of the EBMT

Blood (2021) 138 (Supplement 1): 2876.

https://doi.org/10.1182/blood-2021-151000

Published: 2021

Journal Articles

Cluster of Differentiation 20 Expression and Rituximab Use Do Not Improve Outcome of Classical Hodgkin Lymphoma Patients

Khadega A Abuelgasim, Raed Al Shammari, Saeed Alshieban, Bader Alahmari, MD, Mohsen Alzahrani, Ayman Alhejazi, MD, Ahmed Alaskar, Moussab Damlaj

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-135917

Published: 2020

Journal Articles

Home Care Program for Managing Oncology Patients during COVID-19 Pandemic. a Tertiary Referral Center Experience

Giamal Edin Gmati, MD, Nadine Mabsut, Zainab Matar, Mona Alshami, Husam Shahata, Areej Alkhesaifi, Mohamed Alharbi, Nashmia Almutairi, Ashwaq Alolayan, Mohsen Alzahrani, Abdullah Algarni, Abdulrahman Alhadab, Ayman Hejazi, Bader Alahmari, Abdul-Rahman Jazieh, MD

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-141782

Published: 2020

Journal Articles

Favourable Outcome of Non Myeloablative Allogeneic HSCT in Adult Patients with Severe Sickle Cell Disease: A Single Center Experience of 110 Patients

Mohsen Alzahrani, Bader Alahmari, Ahmed Alaskar, MD FRCPC, Ayman Hejazi, Giamal Edin Gmati, MD, Khadega A. Abuelgasim, Hind Salama, Abdulrahman Raiza, Abdulrahman Alghamdi, Walid Mashaqbeh, Heba Alshobaki, Tahani Alanazy, Maybelle Balili, Muhammad Qureshi, Mazin Ahmed, Husam Mazin Alsadi, MD, Moussab Damlaj

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-139348

Published: 2020

NARROW

Short and Long-Term Toxicities of Allogeneic Stem Cell Transplant for Adult Patients with Sickle Cell Disease

Outpatient Hematopoietic Stem Cell Transplant for Adult Sickle Cell Disease Patients Is Safe, Reduce Inpatient Bed Utilization and Improve Access to Care

An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease

Favorable Fertility Outcome in a Large Cohort of Sickle Cell Disease Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Excellent Outcomes of HLA Matched Related Donor Transplant for Adults with Severe Sickle Cell Disease Using a Non-Myeloablative Conditioning with Thiotepa and Post-Transplant Cyclophosphamide: Multi-Center International Experience

Comparison of Interobserver Agreement between the 4T and the HIT Expert Probability (HEP) Scores: We Agreed Not to Agree

Clinical Features and Outcomes of Hemophagocytic Lymphohistiocytosis Secondary to Lymphoma: Insights from a Tertiary Center in Saudi Arabia

Impact of Genetic Variations on Thrombotic Risk in Saudis with Sickle Cell Disease

Sickle Cell Disease (SCD) Burden on Patients Treated With Hydroxyurea (HU): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)

Effect of ABO Mismatch and RBC Alloimmunization on the Outcomes of Patients with Sickle Cell Disease Undergoing Hematopoietic Stem Cell Transplantation

Early Donor T-Cell Engraftment Is Critical for Immune Tolerance in Reduced Intensity Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide for Sickle Cell Disease: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC 2 )

Outcome of Advanced Stage Diffuse Large B-Cell Lymphoma; Experience from Saudi Arabia

Real Life Analysis of Brentuximab Vedotin (BV) Use As Consolidation Therapy in Patients with Hodgkin's Lymphoma (HL) with High Risk of Relapse after Autologous Stem Cell Transplantation (ASCT). a Retrospective Analysis of the EBMT Lymphoma Working Party

Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC 2 )

Evidence Gaps in the Management of Patients with Sickle Cell Disease (SCD) by Non-specialist Healthcare Professionals (HCPs): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)

Discontinuation of Tyrosine Kinase Inhibitor Therapy and Treatment-Free Remission in Chronic-Phase Chronic Myeloid Leukemia: An Observational Retrospective Multi-Center Study

Higher Efficacy of TBI + Cyclophosphamide Than TBI + Fludarabine As Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia: An Analysis By the Acute Leukemia Working Party of the EBMT

Cluster of Differentiation 20 Expression and Rituximab Use Do Not Improve Outcome of Classical Hodgkin Lymphoma Patients

Home Care Program for Managing Oncology Patients during COVID-19 Pandemic. a Tertiary Referral Center Experience

Favourable Outcome of Non Myeloablative Allogeneic HSCT in Adult Patients with Severe Sickle Cell Disease: A Single Center Experience of 110 Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only